Annual EBITDA
-$69.00 M
+$27.62 M+28.58%
31 December 2023
Summary:
EyePoint Pharmaceuticals annual earnings before interest, taxes, depreciation & amortization is currently -$69.00 million, with the most recent change of +$27.62 million (+28.58%) on 31 December 2023. During the last 3 years, it has fallen by -$33.51 million (-94.43%). EYPT annual EBITDA is now -655.70% below its all-time high of $12.42 million, reached on 30 June 2010.EYPT EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
-$28.95 M
+$1.51 M+4.96%
30 September 2024
Summary:
EyePoint Pharmaceuticals quarterly earnings before interest, taxes, depreciation & amortization is currently -$28.95 million, with the most recent change of +$1.51 million (+4.96%) on 30 September 2024. Over the past year, it has dropped by -$16.46 million (-131.68%). EYPT quarterly EBITDA is now -237.74% below its all-time high of $21.02 million, reached on 30 September 2014.EYPT Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
-$102.30 M
-$16.46 M-19.17%
30 September 2024
Summary:
EyePoint Pharmaceuticals TTM earnings before interest, taxes, depreciation & amortization is currently -$102.30 million, with the most recent change of -$16.46 million (-19.17%) on 30 September 2024. Over the past year, it has dropped by -$4.87 million (-5.00%). EYPT TTM EBITDA is now -923.89% below its all-time high of $12.42 million, reached on 30 June 2010.EYPT TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
EYPT EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +28.6% | -131.7% | -5.0% |
| 3 y3 years | -94.4% | -98.2% | -123.5% |
| 5 y5 years | -65.3% | -118.8% | -155.5% |
EYPT EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -94.4% | +28.6% | -131.7% | +31.6% | -123.5% | at low |
| 5 y | 5 years | -94.4% | +28.6% | -2135.8% | +31.6% | -235.0% | at low |
| alltime | all time | -655.7% | +28.6% | -237.7% | +47.1% | -923.9% | at low |
EyePoint Pharmaceuticals EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$28.95 M(-5.0%) | -$102.30 M(+19.2%) |
| June 2024 | - | -$30.46 M(+5.1%) | -$85.85 M(+10.4%) |
| Mar 2024 | - | -$28.98 M(+108.4%) | -$77.73 M(+12.7%) |
| Dec 2023 | -$69.00 M(-28.6%) | -$13.90 M(+11.3%) | -$69.00 M(-29.2%) |
| Sept 2023 | - | -$12.50 M(-44.1%) | -$97.43 M(-4.5%) |
| June 2023 | - | -$22.35 M(+10.4%) | -$101.98 M(+4.3%) |
| Mar 2023 | - | -$20.25 M(-52.2%) | -$97.78 M(+1.2%) |
| Dec 2022 | -$96.62 M(+92.7%) | -$42.34 M(+148.3%) | -$96.62 M(+34.9%) |
| Sept 2022 | - | -$17.05 M(-6.1%) | -$71.63 M(+3.5%) |
| June 2022 | - | -$18.15 M(-4.9%) | -$69.19 M(+17.3%) |
| Mar 2022 | - | -$19.09 M(+10.0%) | -$58.99 M(+17.6%) |
| Dec 2021 | -$50.15 M(+41.3%) | -$17.35 M(+18.8%) | -$50.15 M(+9.6%) |
| Sept 2021 | - | -$14.61 M(+83.7%) | -$45.77 M(+41.0%) |
| June 2021 | - | -$7.95 M(-22.4%) | -$32.46 M(-7.2%) |
| Mar 2021 | - | -$10.25 M(-21.0%) | -$34.99 M(-1.5%) |
| Dec 2020 | -$35.49 M(-26.1%) | -$12.97 M(+901.8%) | -$35.54 M(+16.4%) |
| Sept 2020 | - | -$1.29 M(-87.6%) | -$30.54 M(-28.1%) |
| June 2020 | - | -$10.47 M(-3.0%) | -$42.47 M(+3.0%) |
| Mar 2020 | - | -$10.80 M(+35.4%) | -$41.25 M(-14.1%) |
| Dec 2019 | -$48.01 M(+15.0%) | -$7.97 M(-39.7%) | -$48.01 M(+19.9%) |
| Sept 2019 | - | -$13.23 M(+43.0%) | -$40.04 M(-31.5%) |
| June 2019 | - | -$9.25 M(-47.3%) | -$58.46 M(-30.8%) |
| Mar 2019 | - | -$17.56 M(-44.5%) | -$84.52 M(+9.5%) |
| Dec 2018 | -$41.75 M(-18.6%) | - | - |
| Sept 2018 | - | -$31.65 M(-10.3%) | -$77.17 M(+50.5%) |
| June 2018 | -$51.30 M(+190.3%) | -$35.30 M(+661.7%) | -$51.28 M(+135.1%) |
| Mar 2018 | - | -$4.63 M(-16.9%) | -$21.81 M(-1.4%) |
| Dec 2017 | - | -$5.58 M(-3.2%) | -$22.13 M(+34.6%) |
| Sept 2017 | - | -$5.76 M(-1.2%) | -$16.43 M(-7.0%) |
| June 2017 | -$17.67 M(-15.0%) | -$5.83 M(+17.7%) | -$17.67 M(-1.7%) |
| Mar 2017 | - | -$4.95 M(-4523.2%) | -$17.97 M(+0.4%) |
| Dec 2016 | - | $112.00 K(-101.6%) | -$17.90 M(-22.3%) |
| Sept 2016 | - | -$7.00 M(+14.1%) | -$23.03 M(+10.7%) |
| June 2016 | -$20.79 M(-384.7%) | -$6.13 M(+25.7%) | -$20.79 M(+5.9%) |
| Mar 2016 | - | -$4.88 M(-2.8%) | -$19.64 M(+0.2%) |
| Dec 2015 | - | -$5.02 M(+5.4%) | -$19.60 M(+6.0%) |
| Sept 2015 | - | -$4.76 M(-4.3%) | -$18.48 M(-353.0%) |
| June 2015 | $7.30 M(-157.7%) | -$4.98 M(+2.8%) | $7.30 M(-14.1%) |
| Mar 2015 | - | -$4.84 M(+24.1%) | $8.50 M(-25.1%) |
| Dec 2014 | - | -$3.90 M(-118.6%) | $11.35 M(-4.3%) |
| Sept 2014 | - | $21.02 M(-655.8%) | $11.86 M(-193.7%) |
| June 2014 | -$12.65 M(+14.6%) | -$3.78 M(+89.9%) | -$12.65 M(+0.3%) |
| Mar 2014 | - | -$1.99 M(-41.2%) | -$12.62 M(-4.3%) |
| Dec 2013 | - | -$3.39 M(-2.8%) | -$13.18 M(+8.2%) |
| Sept 2013 | - | -$3.49 M(-6.9%) | -$12.19 M(+10.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2013 | -$11.04 M(-51.5%) | -$3.75 M(+46.4%) | -$11.04 M(-53.9%) |
| Mar 2013 | - | -$2.56 M(+6.9%) | -$23.95 M(+0.3%) |
| Dec 2012 | - | -$2.40 M(+2.6%) | -$23.88 M(-37.4%) |
| Sept 2012 | - | -$2.33 M(-86.0%) | -$38.13 M(+1.8%) |
| June 2012 | -$22.78 M(+315.8%) | -$16.66 M(+568.8%) | -$37.47 M(+96.3%) |
| Mar 2012 | - | -$2.49 M(-85.0%) | -$19.09 M(+1.0%) |
| Dec 2011 | - | -$16.64 M(+894.1%) | -$18.89 M(+316.3%) |
| Sept 2011 | - | -$1.67 M(-197.5%) | -$4.54 M(-17.2%) |
| June 2011 | -$5.48 M(-144.1%) | $1.72 M(-174.8%) | -$5.48 M(-194.8%) |
| Mar 2011 | - | -$2.29 M(+0.4%) | $5.78 M(-4.2%) |
| Dec 2010 | - | -$2.29 M(-12.5%) | $6.03 M(-33.4%) |
| Sept 2010 | - | -$2.61 M(-120.1%) | $9.06 M(-27.1%) |
| June 2010 | $12.42 M(<-9900.0%) | $12.97 M(-736.0%) | $12.42 M(+795.9%) |
| Mar 2010 | - | -$2.04 M(-377.2%) | $1.39 M(-59.7%) |
| Dec 2009 | - | $736.00 K(-1.5%) | $3.44 M(+61.3%) |
| Sept 2009 | - | $747.00 K(-61.6%) | $2.13 M(-8987.5%) |
| June 2009 | -$24.00 K(-100.0%) | $1.94 M(>+9900.0%) | -$24.00 K(-100.0%) |
| Mar 2009 | - | $14.00 K(-102.5%) | -$56.72 M(-9.0%) |
| Dec 2008 | - | -$571.00 K(-59.5%) | -$62.31 M(-9.3%) |
| Sept 2008 | - | -$1.41 M(-97.4%) | -$68.67 M(-3.8%) |
| June 2008 | -$71.36 M(+166.0%) | -$54.75 M(+880.8%) | -$71.36 M(+32.3%) |
| Mar 2008 | - | -$5.58 M(-19.4%) | -$53.93 M(+11.7%) |
| Dec 2007 | - | -$6.93 M(+68.9%) | -$48.29 M(-3.2%) |
| Sept 2007 | - | -$4.10 M(-89.0%) | -$49.86 M(+10.9%) |
| June 2007 | -$26.82 M(+41.4%) | -$37.32 M(<-9900.0%) | -$44.97 M(+23.6%) |
| Mar 2007 | - | $65.00 K(-100.8%) | -$36.38 M(+0.8%) |
| Dec 2006 | - | -$8.50 M(-1175.4%) | -$36.09 M(+34.1%) |
| Sept 2006 | - | $790.40 K(-102.8%) | -$26.92 M(-1.5%) |
| June 2006 | -$18.98 M(+101.1%) | -$28.73 M(-8264.7%) | -$27.33 M(+100.5%) |
| Mar 2006 | - | $351.90 K(-47.5%) | -$13.63 M(-1.4%) |
| Dec 2005 | - | $670.70 K(+78.8%) | -$13.82 M(-3.6%) |
| Sept 2005 | - | $375.10 K(-102.5%) | -$14.33 M(-1.5%) |
| June 2005 | -$9.44 M(+57.4%) | -$15.03 M(-9470.5%) | -$14.56 M(+143.3%) |
| Mar 2005 | - | $160.40 K(-0.9%) | -$5.98 M(-1.4%) |
| Dec 2004 | - | $161.80 K(+7.4%) | -$6.07 M(-1.5%) |
| Sept 2004 | - | $150.70 K(-102.3%) | -$6.16 M(-1.4%) |
| June 2004 | -$6.00 M(+77.1%) | -$6.46 M(-8954.7%) | -$6.25 M(+81.7%) |
| Mar 2004 | - | $72.90 K(+1.5%) | -$3.44 M(-1.6%) |
| Dec 2003 | - | $71.80 K(+10.6%) | -$3.49 M(-1.6%) |
| Sept 2003 | - | $64.90 K(-101.8%) | -$3.55 M(-1.4%) |
| June 2003 | -$3.39 M(+164.7%) | -$3.65 M(<-9900.0%) | -$3.60 M(-7728.4%) |
| Mar 2003 | - | $16.70 K(+7.7%) | $47.20 K(+54.8%) |
| Dec 2002 | - | $15.50 K(+3.3%) | $30.50 K(+103.3%) |
| Sept 2002 | - | $15.00 K | $15.00 K |
| June 2002 | -$1.28 M(+194.2%) | - | - |
| June 2001 | -$434.60 K | - | - |
FAQ
- What is EyePoint Pharmaceuticals annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for EyePoint Pharmaceuticals?
- What is EyePoint Pharmaceuticals annual EBITDA year-on-year change?
- What is EyePoint Pharmaceuticals quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for EyePoint Pharmaceuticals?
- What is EyePoint Pharmaceuticals quarterly EBITDA year-on-year change?
- What is EyePoint Pharmaceuticals TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for EyePoint Pharmaceuticals?
- What is EyePoint Pharmaceuticals TTM EBITDA year-on-year change?
What is EyePoint Pharmaceuticals annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of EYPT is -$69.00 M
What is the all time high annual EBITDA for EyePoint Pharmaceuticals?
EyePoint Pharmaceuticals all-time high annual earnings before interest, taxes, depreciation & amortization is $12.42 M
What is EyePoint Pharmaceuticals annual EBITDA year-on-year change?
Over the past year, EYPT annual earnings before interest, taxes, depreciation & amortization has changed by +$27.62 M (+28.58%)
What is EyePoint Pharmaceuticals quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of EYPT is -$28.95 M
What is the all time high quarterly EBITDA for EyePoint Pharmaceuticals?
EyePoint Pharmaceuticals all-time high quarterly earnings before interest, taxes, depreciation & amortization is $21.02 M
What is EyePoint Pharmaceuticals quarterly EBITDA year-on-year change?
Over the past year, EYPT quarterly earnings before interest, taxes, depreciation & amortization has changed by -$16.46 M (-131.68%)
What is EyePoint Pharmaceuticals TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of EYPT is -$102.30 M
What is the all time high TTM EBITDA for EyePoint Pharmaceuticals?
EyePoint Pharmaceuticals all-time high TTM earnings before interest, taxes, depreciation & amortization is $12.42 M
What is EyePoint Pharmaceuticals TTM EBITDA year-on-year change?
Over the past year, EYPT TTM earnings before interest, taxes, depreciation & amortization has changed by -$4.87 M (-5.00%)